Posted in | News | Nanomedicine

NanoViricides Honored with IAIR Award for Leadership in Nanomedicine

NanoViricides, Inc. (the "Company") has won the prestigious “IAIR Award” as the “Best North American Company for Leadership in the Nanomedicine Sector.”

The invitation-only award ceremony and gala dinner for the “IAIR Awards - North America” was held at the Yale Club in New York City on Tuesday, April 15th, 2014. IAIR (International Alternative Investment Review) is a publication of EDITRICE LE FONTI® SRL, Milan, Italy.

“We always knew that we are leaders in nanomedicines,” said Anil R. Diwan, PhD, Chairman and President, accepting the award on behalf of the Company, “It is great to be recognized internationally as being the leader by IAIR.”

In another news, the Company reported today that construction of its modern R&D Lab and cGMP Clinical Production facility in Shelton, CT, is nearing completion. The construction of the R&D Lab sections is nearly complete, and construction of the cGMP section is in the final stage. The Company anticipates completion of this total renovation of the facility by June, 2014. Thereafter the project will enter facility testing and validation phase. The Company reports that there have been certain weather related delays that have also affected delivery of certain special equipment.

The Company also reported that it is producing Injectable FluCide™, our most advanced drug candidate, at its existing facilities, in the large quantity needed for the Safety and Toxicology (“Tox Package”) study. The strong safety observed in preliminary safety studies resulted in requirement of a very large quantity for the Tox Package study. Notably, the drug candidate was found to be safe even at the maximum feasible dosage level in a small animal study. The Company reports that it has successfully scaled up the production of injectable FluCide at its current facility.

In addition, the Company reports that all of its drug development programs are progressing satisfactorily.

Our Injectable FluCide broad-spectrum anti-influenza treatment is designed for treating severe influenza in hospitalized patients. There are approximately 300,000 cases of hospitalization by Influenza or Influenza-like-illness (ILI) in the USA alone, in non-pandemic years, with approximately 30,000 deaths annually. The Company anticipates that our highly effective anti-influenza drug could reduce the extent of hospitalization significantly, thereby providing multi-billion-dollar savings to the healthcare system.

The market for such an effective drug for hospitalized influenza cases alone has been estimated at about $1Bn worldwide. The Company believes that when the drug becomes available for use, the initial demand for our injectable FluCide for treating hospitalized cases could be satisfied from production at our new cGMP facility. Currently, no effective therapy exists for severe or hospitalized influenza.

About IAIR Awards:

IAIR Awards ( is one of the world's leading ranking and prize for excellences in global economy and sustainability. It is made up of the scientific committee of IAIR® and along with a team of dedicated legal, economic and financial journalists in over 120 countries worldwide. We conduct an online survey through our 50,000+ readers to provide to our judging panel which is composed of the editorial staff of IAIR - Excellence in Global Economy and Sustainability and International Family Office Magazine to make the selection of the final award winners. The main part of the evaluation, therefore, is obtained from the online survey and our readers' votes. The judging panel is composed of the editorial staff of IAIR - Excellence in Global Economy and Sustainability and International Family Office Magazine. The judging panel is impartial and seeks to reward genuine and outstanding success and performance in the global finance and global economic field. EDITRICE LE FONTI® SRL (IAIR® GROUP / IAIR AWARDS®) is a research institute and a global independent publishing house headquartered in Milan with more than 10 years of experience in the publishing field. It publishes IAIR (International Alternative Investment Review) and IAIREVIEW.ORG.



Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    NanoViricides, Inc. (2019, February 11). NanoViricides Honored with IAIR Award for Leadership in Nanomedicine. AZoNano. Retrieved on April 24, 2024 from

  • MLA

    NanoViricides, Inc. "NanoViricides Honored with IAIR Award for Leadership in Nanomedicine". AZoNano. 24 April 2024. <>.

  • Chicago

    NanoViricides, Inc. "NanoViricides Honored with IAIR Award for Leadership in Nanomedicine". AZoNano. (accessed April 24, 2024).

  • Harvard

    NanoViricides, Inc. 2019. NanoViricides Honored with IAIR Award for Leadership in Nanomedicine. AZoNano, viewed 24 April 2024,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.